Burrows Francis
Chief Scientific Officer
Burrows Francis has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Jan 27, 2026.
On the most recent filing, Burrows Francis is listed as Chief Scientific Officer at Kura Oncology, Inc. Inside the rolling window, Burrows Francis reported no open-market purchases and 2 open-market sales totaling $243K in KURA. The largest disclosed transaction in the window is a sale of 23,726 KURA shares on Dec 18, 2025, worth $232K.
Companies traded
Other insiders at KURA
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$243K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Burrows Francis made?
Burrows Francis has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2025.
Which companies does Burrows Francis trade?
Burrows Francis has filed SEC Form 4 disclosures for 1 company, including KURA.
When was Burrows Francis's most recent SEC Form 4 filing?
Burrows Francis's most recent SEC Form 4 filing on Tracefour is dated Jan 27, 2026.
What is Burrows Francis's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Burrows Francis is listed as Chief Scientific Officer.
What is Burrows Francis's total buy and sell value in the current window?
Inside the rolling retention window, Burrows Francis bought $0 and sold $243K based on SEC Form 4 filings.
What was Burrows Francis's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 23,726 KURA shares on 2025-12-18, worth $232K, per SEC Form 4 filings.